Company: IMRX
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077655
Chunk: 39

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: S-3
Chunk 39
---
 nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.**

#### Subject to Completion, dated August 13, 2025.

### PROSPECTUS SUPPLEMENT
**(To Prospectus dated , 2025)**

#### Up to $100,000,000

#### Class A Common Stock
**We have entered into an equity distribution agreement, or Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, relating to the sale of shares of our Class A common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Equity Distribution Agreement, we may offer and sell Class A common stock having an aggregate offering price of up to $100,000,000 from time to time through Piper Sandler, acting as our sales agent.

Our Class A common stock is listed on the Nasdaq Global Market under the symbol “IMRX.” On August 12, 2025, the closing price of our Class A common stock was $3.25 per share.

Upon delivery of a placement notice, and subject to our instructions in that notice and the terms and conditions of the Equity Distribution Agreement generally, Piper Sandler may sell our Class A common stock by any method permitted by law deemed to be an “at the market offering” as defined by Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Piper Sandler is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Piper Sandler and us, to sell on our behalf all of the Class A common stock requested to be sold by us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Piper Sandler will be entitled to compensation at a fixed commission rate of up to 3.00% of the gross sales price per Class A common stock sold under the Equity Distribution Agreement. In connection with the sale of Class A common stock on our behalf, Piper Sandler may be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Piper Sandler may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Piper Sandler with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 193